EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The structural basis for LRRK2’s activation and autoinhibition

Amalia Villagran Suarez, Kathryn S Hatch, Tatyana Bodrug, Wei Gai, Katherine J Surridge, Elizabeth Moussikhina, Kendrick H V Nguyen, Marta Sanz-Murillo, Robert Callahan, Erica Xiong, Delisa Ramos, Lawrence Zhu und 7 weitere

Cell · 2026-10 · 189 (20) · 6460-6473.e7

DOI: 10.1016/j.cell.2026.07.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-10. Verfasst von Amalia Villagran Suarez und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Howard Hughes Medical Institute, NIGMS NIH HHS, The Michael J Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the second most common cause of autosomal-dominant Parkinson's disease (PD), and increased LRRK2 kinase activity is also observed in idiopathic PD, making LRRK2 a major actionable therapeutic target. LRRK2 is a 286-kDa multidomain enzyme containing a Ras-like GTPase (ROC) and a kinase domain. Using cryo-electron microscopy (cryo-EM), biochemical reconstitution, and cell-based assays, we show that the ROC GTPase governs switching between autoinhibited and active states: GTP binding promotes activation, whereas GDP binding enforces autoinhibition. Two common PD-linked mutations, G2019S and R1441C/G/H, activate LRRK2 through distinct structural mechanisms, revealing genotype-specific routes to dysregulation. These findings provide a unified framework for understanding LRRK2 regulation with broad therapeutic implications. Stabilizing the guanosine diphosphate (GDP)-bound state may inhibit LRRK2 by maintaining autoinhibition, whereas promoting the GTP-bound state could be advantageous in specific cellular contexts, such as the lung, where increased LRRK2 kinase activity may play protective or regulatory roles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2HumansCryoelectron MicroscopyModels, MolecularGuanosine DiphosphateParkinson DiseaseAnimalsMutationGuanosine Triphosphate

Stichwörter der Autor:innen

G2019SGTPaseLRRK2Parkinson’s diseaseR1441CR1441Hactivationautoinhibitioncryo-EMkinase

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanGuanosine DiphosphateGuanosine Triphosphate

Autor:innen und Institutionen

  • Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
  • Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Institute of Pharmaceutical Chemistry and Structural Genomics Consortium, Goethe-University Frankfurt am Main, Frankfurt, Germany.
  • Department of Biochemistry, University of Utah, Salt Lake City, UT 84132, USA.
  • Institute of Pharmaceutical Chemistry and Structural Genomics Consortium, Goethe-University Frankfurt am Main, Frankfurt, Germany; LRRK2 Investigative Therapeutics Exchange (LITE), New York, NY 10120, USA.
  • Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; LRRK2 Investigative Therapeutics Exc…

Förderung

  • Howard Hughes Medical Institute
  • NIGMS NIH HHS
  • The Michael J Fox Foundation for Parkinson's Research
  • National Parkinson Foundation
  • NIH National Institute of General Medical Sciences
  • Structural Genomics Consortium

Zitieren

APA

Villagran Suarez, A., Hatch, K. S., Bodrug, T., Gai, W., Surridge, K. J., Moussikhina, E., Nguyen, K. H. V., Sanz-Murillo, M., Callahan, R., Xiong, E., Ramos, D., Zhu, L., Dederer, V., Mathea, S., Iwasa, J., Knapp, S., Shokat, K. M., Reck-Peterson, S. L., & Leschziner, A. E. (2026). The structural basis for LRRK2’s activation and autoinhibition. Cell, 189(20), 6460-6473.e7. https://doi.org/10.1016/j.cell.2026.07.027

Vancouver

Villagran Suarez A, Hatch KS, Bodrug T, Gai W, Surridge KJ, Moussikhina E, et al. The structural basis for LRRK2’s activation and autoinhibition. Cell. 2026;189(20):6460-6473.e7. doi:10.1016/j.cell.2026.07.027

BibTeX
@article{VillagranSuarez2026,
  author = {Villagran Suarez, Amalia and Hatch, Kathryn S and Bodrug, Tatyana and Gai, Wei and Surridge, Katherine J and Moussikhina, Elizabeth and Nguyen, Kendrick H V and Sanz-Murillo, Marta and Callahan, Robert and Xiong, Erica and Ramos, Delisa and Zhu, Lawrence and Dederer, Verena and Mathea, Sebastian and Iwasa, Janet and Knapp, Stefan and Shokat, Kevan M and Reck-Peterson, Samara L and Leschziner, Andres E},
  title = {The structural basis for LRRK2’s activation and autoinhibition},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {20},
  pages = {6460--6473.e7},
  doi = {10.1016/j.cell.2026.07.027}
}
Kostenlos starten →